Prof. Jin Wang 王晋
Chief Physician, Professor
Department of Bone and Soft Tissue Tumors, Sun Yat-sen University Cancer Center, Guangzhou
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Bone and soft tissue tumors, including bone metastases, spinal tumors, osteosarcoma, giant cell tumor of bone, chondrosarcoma, Ewing sarcoma, synovial sarcoma, and undifferentiated sarcoma.
Dr. Wang is Professor, Chief Physician, Doctoral Supervisor, and Director of the Department of Bone and Soft Tissue. With 21 years of experience, Dr. Wang completed clinical fellowship training in Australia (2002) and postdoctoral research training in the US (2003). Dr. Wang visited Queen Mary Hospital, University of Hong Kong, in 2013.
Professional roles
- Member, Bone Tumor Group, 10th Committee of Orthopedics Branch, Chinese Medical Association
- Member, Pelvic Ring and Soft Tissue Group, Sarcoma Professional Committee, China Anti-Cancer Association
- Deputy Leader and Secretary, Bone Tumor Group, Guangdong Orthopedic Association
- Global Member, International Society of Limb Salvage (ISOLS)
Name order: in Chinese the family name comes first (Wang Jin). Papers usually list the name as Jin Wang or Wang J.
Selected publications
110 papers on PubMed matched by name and affiliation; 43 as first or senior author since 2016. Most recent first- or senior-author papers:
- Abdom Radiol (NY), 2026 (senior author): Dual-energy CT-derived multiparameters for noninvasive prediction of vessels encapsulating tumor clusters and microvascular invasion in hepatocellular carcinoma. PubMed 42118276
- J Shoulder Elbow Surg, 2026 (senior author): Clinical Outcomes of a Customized 3D-printed Arthrodesis Prosthesis for Reconstruction of Segmental Defects following Tumor Resection in the Proximal Humerus. PubMed 42887772
- Clin Cancer Res, 2026 (senior author): Phase III Trial of Pegylated Liposomal Doxorubicin for Patients with Advanced and Refractory Desmoid Tumors. PubMed 41504634
- Drug Des Devel Ther, 2026 (senior author): Lenvatinib in Combination with PD-1 Blockades as Re-Challenging Treatment for Patients with Metastatic Soft Tissue Sarcoma Following TKI Treatment Failure: A Retrospective Study. PubMed 41939428
- Mol Cancer, 2025 (senior author): Targeting OxLDL-mediated CD36 + CAF reprogramming potentiates PD-1 immunotherapy in osteosarcoma. PubMed 41413558
- Biomaterials, 2025 (senior author): Innovative sarcoma therapy using multifaceted nano-PROTAC-induced EZH2 degradation and immunity enhancement. PubMed 40262462
- Ann Surg Oncol, 2025 (senior author): ASO Author Reflections: Limited Survival Benefit from Neoadjuvant Chemotherapy in ER+/HER2- Breast Cancer. PubMed 40382451
- Ann Surg Oncol, 2025 (first author): Long-term Outcomes for Neoadjuvant Versus Adjuvant Chemotherapy in ER+/HER2- Locally Advanced Breast Cancer. PubMed 40263225
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital. This name is shared by other researchers, so we checked that most papers list this doctor's hospital and department.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion